Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management
Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 receptor/ligand have revolutionized cancer treatment, achieving unprecedented efficacy in numerous malignancies. Despite the excellent therapeutic effects of ICIs, medications, such as...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2022-04-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://ies.ijo.cn/en_publish/2022/4/20220419.pdf |
| _version_ | 1819205491147931648 |
|---|---|
| author | Yu-Wen Zhou Qian Xu Yan Wang Ruo-Lan Xia Ji-Yan Liu Xue-Lei Ma |
| author_facet | Yu-Wen Zhou Qian Xu Yan Wang Ruo-Lan Xia Ji-Yan Liu Xue-Lei Ma |
| author_sort | Yu-Wen Zhou |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 receptor/ligand have revolutionized cancer treatment, achieving unprecedented efficacy in numerous malignancies. Despite the excellent therapeutic effects of ICIs, medications, such as pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, and durvalumab, typically cause a broad spectrum of toxicity events termed as immune-related adverse events (irAEs). Out of all irAEs, ophthalmic adverse events occur infrequently and are not comprehensively recognized. The current understanding of ophthalmic irAEs is mainly derived from case reports and case series. In this review, based on relevant articles in the literature and current evidence, we summarize the incidences, manifestations, diagnoses, underlying mechanisms, treatments, and outcomes of ophthalmic irAEs and discuss possible management strategies. A better understanding of these features is critical for managing patients with ICI-associated ophthalmic adverse events. |
| first_indexed | 2024-12-23T04:52:33Z |
| format | Article |
| id | doaj.art-3df8fb7f37be46daa3effaf0b83af76b |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-12-23T04:52:33Z |
| publishDate | 2022-04-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-3df8fb7f37be46daa3effaf0b83af76b2022-12-21T17:59:25ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982022-04-0115464665610.18240/ijo.2022.04.1920220419Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and managementYu-Wen Zhou0Qian Xu1Yan Wang2Ruo-Lan Xia3Ji-Yan Liu4Xue-Lei Ma5Ji-Yan Liu and Xue-Lei Ma. Department of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan Province, China. liujiyan1972@163.com; drmaxuelei@gmail.comWest China Medical Publishers, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, ChinaDepartment of Oncology, West China Hospital, the First People's Hospital of Long Quan Yi District, Chengdu 610041, Sichuan Province, ChinaDepartment of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, ChinaDepartment of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, ChinaDepartment of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, ChinaImmune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 receptor/ligand have revolutionized cancer treatment, achieving unprecedented efficacy in numerous malignancies. Despite the excellent therapeutic effects of ICIs, medications, such as pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, and durvalumab, typically cause a broad spectrum of toxicity events termed as immune-related adverse events (irAEs). Out of all irAEs, ophthalmic adverse events occur infrequently and are not comprehensively recognized. The current understanding of ophthalmic irAEs is mainly derived from case reports and case series. In this review, based on relevant articles in the literature and current evidence, we summarize the incidences, manifestations, diagnoses, underlying mechanisms, treatments, and outcomes of ophthalmic irAEs and discuss possible management strategies. A better understanding of these features is critical for managing patients with ICI-associated ophthalmic adverse events.http://ies.ijo.cn/en_publish/2022/4/20220419.pdfimmune checkpoint inhibitorophthalmological adverse eventsuveitisneuro-ophthalmic toxicityretinopathy |
| spellingShingle | Yu-Wen Zhou Qian Xu Yan Wang Ruo-Lan Xia Ji-Yan Liu Xue-Lei Ma Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management International Journal of Ophthalmology immune checkpoint inhibitor ophthalmological adverse events uveitis neuro-ophthalmic toxicity retinopathy |
| title | Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management |
| title_full | Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management |
| title_fullStr | Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management |
| title_full_unstemmed | Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management |
| title_short | Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management |
| title_sort | immune checkpoint inhibitor associated ophthalmic adverse events current understanding of its mechanisms diagnosis and management |
| topic | immune checkpoint inhibitor ophthalmological adverse events uveitis neuro-ophthalmic toxicity retinopathy |
| url | http://ies.ijo.cn/en_publish/2022/4/20220419.pdf |
| work_keys_str_mv | AT yuwenzhou immunecheckpointinhibitorassociatedophthalmicadverseeventscurrentunderstandingofitsmechanismsdiagnosisandmanagement AT qianxu immunecheckpointinhibitorassociatedophthalmicadverseeventscurrentunderstandingofitsmechanismsdiagnosisandmanagement AT yanwang immunecheckpointinhibitorassociatedophthalmicadverseeventscurrentunderstandingofitsmechanismsdiagnosisandmanagement AT ruolanxia immunecheckpointinhibitorassociatedophthalmicadverseeventscurrentunderstandingofitsmechanismsdiagnosisandmanagement AT jiyanliu immunecheckpointinhibitorassociatedophthalmicadverseeventscurrentunderstandingofitsmechanismsdiagnosisandmanagement AT xueleima immunecheckpointinhibitorassociatedophthalmicadverseeventscurrentunderstandingofitsmechanismsdiagnosisandmanagement |